In a preclinical mouse model of melanoma, anti-PD1 immunotherapy triggered changes in both tumor-infiltrating and circulating T cell subsets, with a marked increase in EM and CM CD8+ T cells associated with durable responses (38). This evidence concerns the gene CD8A and neoplasm.